Merck Responds To Questions About Adverse Events Reported Following Vaccination With GARDASIL�
Merck Responds To Questions About Adverse Events Reported Following Vaccination With GARDASIL�
Merck issued the following statement to address questions about adverse events reported in people who had received GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant]. Merck has analyzed the adverse events reported for GARDASIL relating to the recent reports of death and paralysis, and based on the data available to Merck, believes that no safety issue related to the vaccine has been identified.
What next?
Posting Komentar